key: cord-0756158-7odtbo8v authors: Liu, T.; He, Z.; Huang, J.; Yan, N.; Chen, Q.; Huang, F.; Zhang, Y.; Akinwunmi, O. M.; Akinwunmi, B. O.; Zhang, C. J. P.; Wu, Y.; Ming, W.-k. title: The comparison of vaccine hesitancy of COVID-19 vaccination in China and the United States date: 2021-05-02 journal: nan DOI: 10.1101/2021.04.29.21256317 sha: 7c217e3e5547433e0fe6d3e1b49f57ca63492d38 doc_id: 756158 cord_uid: 7odtbo8v Background: To investigate the differences in vaccine hesitancy and preference of the currently available COVID-19 vaccines between two countries, viz. China and the United States (US). Method: A cross-national survey was conducted in both China and the US, and discrete choice experiments as well as Likert scales were utilized to assess vaccine preference and the underlying factors contributing to the vaccination acceptance. A propensity score matching (PSM) was performed to enable a direct comparison between the two countries. Results: A total of 9,077 (5,375 and 3,702, respectively, from China and the US) respondents have completed the survey. After propensity score matching, over 82.0% respondents from China positively accept the COVID-19 vaccination, while 72.2% respondents form the US positively accept it. Specifically, only 31.9% of Chinese respondents were recommended by a doctor to have COVID-19 vaccination, while more than half of the US respondents were recommended by a doctor (50.2%), local health board (59.4%), or friends and families (64.8%). The discrete choice experiments revealed that respondents from the US attached the greatest importance to the efficacy of COVID-19 vaccines (44.41%), followed by the cost of vaccination (29.57%), whereas those from China held a different viewpoint that the cost of vaccination covers the largest proportion in their trade-off (30.66%), and efficacy ranked as the second most important attribute (26.34%). Also, respondents from China tend to concern much more about the adverse effect of vaccination (19.68% vs 6.12%) and have lower perceived severity of being infected with COVID-19. Conclusion: While the overall acceptance and hesitancy of COVID-19 vaccination in both countries are high, underpinned distinctions between countries are observed. Owing to the differences in COVID-19 incidence rates, cultural backgrounds, and the availability of specific COVID-19 vaccines in two countries, the vaccine rollout strategies should be nation-dependent. A pneumonia-like disease outbreak, now named the 2019 Coronavirus disease (COVID-19) caused by a 80 newly identified coronavirus, a.k.a., the severe acute respiratory syndrome (SARS)-CoV-2, has swept 81 the globe in early 2020 1 . Although its exact origin remains unknown, and detailed knowledge of its 82 transmission is still limited, this global pandemic has become the most serious public health threat from 83 a respiratory virus since the 1918 H1N1 influenza pandemic 2-4 . One year after the commencement of the 84 pandemic 5 , the COVID-19 is continuously imposing tremendous burdens on the public health systems 85 and the economy globally 6,7 . As of early March 2021, 219 countries or regions have reported confirmed 86 cases 8 , with over 120 million confirmed cases and over 2·66 million deaths, and a case fatality rate over 87 2·21% worldwide 9 . 88 Various public health measures, specifically, non-pharmaceutical interventions (NPIs) that showed 89 effectiveness in previous infection outbreaks (e.g., mass facemask use, social distancing, and home 90 quarantine) have been implemented by governments to contain the spread of SARS-CoV-2 2,10-12 . While 91 the effectiveness of these public health measures in this outbreak remains to be determined, these NPIs 92 may carry a high economic cost, leading to a long war of attrition in society 13 . 93 Therefore, massive vaccination coverage is considered as a prerequisite to achieve herd immunity and 94 therefore curb the COVID-19 pandemic 14 103 Some studies have found that COVID-19 vaccines acceptance varied to a large extent across countries 104 and regions before the vaccine becomes available, and the vaccine hesitancy of COVID-19 is increasing 105 globally 25, 26 . This may influence the vaccination coverage and hinder the establishment of herd 106 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101/2021.04.29.21256317 doi: medRxiv preprint immunity. Interestingly, an increasing vaccine hesitancy is being noticed among Chinese residents and 107 some Asian countries where the transmission of COVID-19 has been well-controlled, specifically, when 108 the vaccines are completely free in some countries, and such phenomena may be attributable to the low 109 perceived benefits of the vaccines and low perceived risks of the COVID-19 pandemic, and most 110 importantly, the low perceived efficacy and the increasingly high skepticism of the efficacy and safety 111 of the currently COVID-19 vaccines 27 . Therefore, it is urgently to find the hindering factors and further 112 promote the COVID-19 vaccination to achieve the herd immunity. 113 Vaccine hesitancy is multifactorial, attributable to general misinformation spread, perceived risks of 114 disease, perceived efficacy and safety of vaccines, attitudes and demand of vaccines, cultural and 115 religious factors and other unspecific factors 28, 29 . China and the United States (US) are two of the 116 representative countries that are among the major countries hardest hit by the pandemic 30 , and both have 117 large population but very different cultural and religious systems 31 ; hence residents' acceptance to 118 COVID-19 vaccination of the two countries could be strategically significant for further vaccines 119 promotion and herd immunity. 120 Nevertheless, the direct comparison between countries could be biased and irrelevant owing to the 121 high heterogeneity and confounding effects, hence in the present study, the propensity score matching 122 (PSM) was utilized to compare the two population. And the following aims were addressed: 1) to 123 investigate on the census-level acceptance and preference of residents and further exploring the 124 influencing factors underlying their decision-making towards COVID-19 vaccination; 2) to compare the 125 two countries in a statistically comparable way to demonstrate the vaccine hesitancy in two countries 126 and further provide insights into future strategies of the large-scale COVID-19 vaccination coverage in 127 two countries. , including standard demographic and socio-economic questions including age, sex, level of 138 education, annual income, and marital status, followed by one set of discrete choice experiments (DCE) 139 and questions about risk perception, COVID-19 impact, attitudes, and acceptance of and attitudes 140 towards vaccines against COVID-10 during the pandemic. Prior to formal data collection, a pilot study 141 in China had been conducted to evaluate the content validity and the reliability of the questions with 142 both experts and general populations, and a group of experts was consulted to improve semantics and 143 readability. The inclusion criteria were respondents aged 18 years and above without cognitive impairments (self-147 report). Respondents were randomly recruited and selected through multiple international online panel 148 providers (MTurk and Dynata) and by nearly 100 experienced volunteers recruited across China using a 149 stratified sampling method. No personally identifiable information was collected. A total of 12,959 150 respondents was recruited, with a total of 9077 respondents (5,375 and 3,702 respondents from China 151 and the US respectively) included in our study. 152 153 Data collection 154 The survey data were collected between January 29 and February 13, 2021. The respondents were 155 required to provide a randomly generated code after completing the survey to ensure that the 156 respondents are real persons instead of robots. All the questions were close ended, with tick boxes 157 provided for responses and no question skipping allowed, and no data would be stored if the website of 158 the questionnaire was closed before completion. Hence, no missing data were generated. 159 General acceptance was defined as scoring greater than 6 with regards to answering the question 160 "How do you rate your willingness and acceptance to get COVID-19 vaccination? (if the vaccines are 161 generally available)", and the acceptance under social cues was defined as scoring greater than 6 for the 162 acceptance for COVID-19 vaccines if the vaccination was recommended by the respondents' family 163 members, friends or employers. Countries were categorized as developed and developing countries 164 according to United Nations country classification 2 . Educational level was further classified into four 165 groups, where "low" signifies respondents reporting having not finished a secondary education (high 166 school); "medium" signifies those who had completed secondary, vocational, or equivalent degrees; and 167 "high" group consisted of those who had completed a tertiary or bachelor's degree and "very high" 168 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 2, 2021. ; indicates postgraduate work. Moreover, two external COVID-19-related variables were added abided by 169 the Method reported by Lazarus et al., namely the total SARS-CoV-2 positive cases per million persons 170 and total SARS-CoV-2 deaths per million persons as reported by Worldometer on 21 January 2021 1, 2 . 171 For COVID-19 cases per million in population, "High" was defined as more than 10,000 cases per 172 million people, "medium" as between 1,000 and 10,000 cases per million people, and "low" was defined 173 as below 1,000 cases per million people. For COVID-19-specific mortality cases per million in the 174 population, "High" was defined as more than 1,000 deaths per million people, "medium" as between 175 100 and 1,000 deaths per million people, and "low" was defined as below 100 deaths per million people. 176 177 Survey design 178 The questionnaire consists of three sections with a total of 55 items that required a response. In the first 179 section, respondents responded to provide social-demographic information regarding age, sex, 180 educational level, occupation, income level, nationality and marital status. Additionally, respondents 181 were required to rate their willingness and acceptance to get vaccinated from "totally unwilling" to 182 "totally willing" with and without social cues. And the questions were "How do you rate your 183 willingness and acceptance of getting vaccination?" and "How do you rate your willingness and 184 acceptance if your friends, family members, neighbors etc. recommend you do so?", respectively. Also, 185 respondents responded to questions related to COVID-19 infection history as well as major source of 186 information with regard to COVID-19 vaccines. 187 In the second section, DCE was used to further explore respondents' preference of the currently 188 available vaccines. Specifically, vaccine attributes and their levels were identified and retrieved through 189 relevant literature and several vaccines on the market, and the attributes were then ranked, categorized 190 and refined by a group of experts in the field of public health and vaccination 3, 4 . A total of six attributes 191 were identified and a two-vaccine profile was randomly adopted for the DCE design. The detailed 192 description of the attributes and levels are summarized in Table S2 . During the survey, respondents were 193 asked to make a series of hypothetical choices and estimate their preference for different attributes of the 194 vaccine based on scenarios. 195 In addition, to assess respondents' attitudes toward COVID-19 and the acceptance of vaccination and their influencing factors, questions were designed based on the five-concept health 197 belief model and other frameworks, as reported by various previous studies to assess vaccine acceptance 198 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table S3 . Later, the set of covariates 214 was determined by at best minimizing the residual confounding factors, where a logistic regression 215 model was performed to estimate the propensity scores for each groups of respondents, and the covariate 216 imbalance testing was reported in the Table S5 . Finally, a total of 3,436 respondents, with half from 217 China and the other half from the US, were matched using propensity scores from the total 12,959 218 respondents, with the covariates being sex, age, and annual income. us better predict the level of preference any vaccines might achieve. And the whole simulation were 249 done in two steps: 1) Subject the respondent's total utilities for the product to the exponential 250 transformation, specifically as and 2) rescale the results to a total of 100% 34 . Respondents' characteristics 254 The present study conducted a large-scale self-administered online survey in China and US. A total of 255 9077 respondents (5,375 and 3,702 respondents from China and the US respectively), who have 256 completed the survey, were selected and further analyzed in the present study. Concerning the pre-PSM 257 samples, the respondents from the United States tended to be higher-educated and earning more money 258 annually compared to respondents from China. For the two respondent groups, the majority of the 259 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. ; respondents were female (55·3% for China, 51·8% for the US), and 47·8% of the respondents in China 260 and 67·6% of those in the US hold a bachelors' degree or higher. After PSM for age, sex, education, 261 annual income, and occupation, no statistically significant discrepancies could be discerned between the 262 respondents from the two countries in demographic characteristics (P = 1·00 for age, sex, education, 263 annual income and occupation). Generate hesitancy and participants' vaccination history 266 As pre-PSM listed in Table 1 (Table S1 ). And generally, more than half of the US respondents were recommended to get 277 vaccination, either by local health board (59·4%), or by friends or families (64·8%). 278 The influence of demographic factors on the average rating of hesitancy of COVID-19 vaccination 279 between the two countries for were shown in Table S1 , and the detailed subgroup analysis of the 280 hesitancy by sex, age intervals, education, occupation and annual income were shown in Figure S1 -S5, 281 respectively. Also, proportion of vaccine hesitancy from China generally smaller than those from the US, 282 except for the respondents with a master's academic degree, or with an annual income over 70,000 USD, 283 or with a skilled, agricultural, forestry and fishery related occupations. In both China and the US, 284 respondents' vaccination hesitancy increased with the academic degree from bachelor's degree. 285 Moreover, being female and higher educated, as well as themselves being infected or friends or families 286 around being infected served as contributor for the respondents hesitating the vaccines, as shown in 287 Table S1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101/2021.04.29.21256317 doi: medRxiv preprint Post-PSM participants' vaccine preference, attributes and level importance. 290 The relative attributes' importance compared between the United States and China was shown in Figure 291 3. After PSM, we found respondents from the US attached the greatest importance to the efficacy of The post-PSM preference comparison between sex in both countries is showed in Figure S6 . For 308 respondents from the US, first, both male and female respondents ranked the efficacy of COVID-19 309 vaccines as the most essential attribute, and the efficacy was even slightly more important for female 310 (male: 43·12%, female 45·07%). while for respondents from China, the cost of vaccination had the 311 greatest relative importance, and slightly more important for female (male: 28·85%, female: 31·45%). 312 Similarly, the efficacy of COVID-19 vaccines also accounted more for female respondents than male 313 respondents (male: 26·36%, female: 26·02%). Behavioral and psychological results 330 The Likert Scale, as presented in Table S1 , indicated that generally, the respondents had a highly is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101/2021.04.29.21256317 doi: medRxiv preprint sampling method, hence the results may demonstrate the census-level investigation in two countries. 350 Generally, majority of the respondents in both countries had high acceptance regarding the COVID-19 351 vaccination, either general acceptance or acceptance under recommendation from friends, family or 352 employers. 353 In our study, we found that respondents from China have a relatively higher acceptance than those 354 from the US, and when compared to the studies conducted before the vaccine become available or even (Table S1 ). And 366 studies have found an association between the incidence of diseased population and perceived risks, and 367 low risk perception was also associated with the respondents trusting health professionals and health 368 officials for information on COVID-19 41 . Public concern about vaccine safety and efficacy has 369 frequently been reported as one of the major obstacles to vaccination acceptance, specifically when the vaccination reported in China; however, the vaccination rate remains below 10% 48 . There is still a huge 379 gap from achieving herd immunity, which requires 70% to 90% vaccination rate as some experts 380 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101/2021.04.29.21256317 doi: medRxiv preprint estimated 49,50 . In contrast, the vaccination rate in the US has reached 30% (at least one dose) 51 with 381 103·35 million people receiving one or more doses cumulative . And therefore, although, vaccination 382 growth rate seems to be more rapid than the US from March 24, 2021, the speed is not rapid enough to 383 reach herd immunity in short term, eventually, the relative low level of vaccination rate in China may 384 force China to lose its advantage in COVID-19 epidemic control 52 . Therefore, improving the speed of 385 vaccination is a top priority currently for all countries around the world to terminate the pandemic. 386 In both pre-PSM and post-PSM samples, we found that while the respondents from China attached 387 more importance to cost, those from US attached more to efficacy. This finding may strongly correlate 388 with local COVID-19 incidence and mortality rate, namely the perceived risk for the public to be . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 2, 2021. The duration of vaccines 12·03% The cost of vaccination 29·57% Adverse effect 19·68% Efficacy 26·34% The duration of vaccines 12·03% The cost of vaccination 30·66% Time for the vaccine starting working 1·93% Clinical features of patients infected with 2019 novel coronavirus 500 in Wuhan, China The deadly coronaviruses: The 2003 SARS pandemic and the 502 2020 novel coronavirus epidemic in China A familial cluster of pneumonia associated with the 2019 novel 504 coronavirus indicating person-to-person transmission: a study of a family cluster Adoption and impact of non-pharmaceutical 507 interventions for COVID-19 Disease and healthcare burden of COVID-19 510 in the United States When will the COVID-512 19 pandemic end? Effects of non-pharmaceutical interventions on COVID-19 523 cases, deaths, and demand for hospital services in the UK: a modelling study Prevention CfDCa. Different COVID-19 vaccines CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, 530 phase 1/2 clinical trial Sputnik V COVID-19 vaccine candidate appears safe and effective COVID vaccines and safety: what the research says Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination Sinovac's COVID-19 vaccine 78% effective in phase 3 trial in Brazil Looking beyond COVID-19 vaccine phase 3 trials Overcoming COVID-19 Vaccine Hesitancy. 2021. 540 23. CDC. About Variants of the Virus that Causes COVID-19 CDC. Science Brief: Emerging SARS-CoV-2 Variants A global survey of potential acceptance of a COVID-544 19 vaccine Confidence and Receptivity for COVID-19 Vaccines: A Rapid 546 Systematic Review. Vaccines (Basel) China's low vaccination rate risks delaying return to normal, warns leading medical 548 expert Zhong Nanshan COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine 551 Which factors are important in adults' uptake of a 590 (pre)pandemic influenza vaccine? Fauci says herd immunity could require nearly 90% to get coronavirus vaccine Not being vaccinated is very dangerous and will suffer! Latest reminder from Zhong 599 How to deal with vaccine hesitancy? Addressing vaccine hesitancy: The potential 604 value of commercial and social marketing principles and practices International collaboration and covid-19: what are we doing 606 and where are we going? Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports 608 of blood clots Acceptance of vaccinations in pandemic 610 outbreaks: a discrete choice experiment